Novel Drug Product Creation with new composition-of-Matter IP
Our technology is a powerful Intellectual Property (IP) engine
Topical therapies are the therapeutic pillar for many diseases, but traditional water- or oil-based formulations have significant limitations that may influence efficacy and safety.
EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It dramatically increases the residual time on the eye from seconds to hours and enables high bioavailability of active pharmaceutical ingredients (API) with excellent tolerability and safety while reducing systemic exposure due to a small drop size (<12 µL).
Thereby EyeSol® unlocks the full potential of APIs by generating novel drug products often even with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.
Novaliq Ophthalmic Pipeline
Dry Eye Disease & General Ophthalmology
EyeSol® Product | Indication | Preclinics | Phase II | Phase III | NDA | Market |
---|---|---|---|---|---|---|
Vevizye® (0.1% ciclosporine in EyeSol®) |
Dry Eye Disease (anti-inflammatory) |
Europe
|
MAA submitted to EMA |
|||
BTQ1902 (timolol 0.5% in EyeSol®) |
Dry Eye Disease (Elevated Intraocular Pressure) |
Global
FDA EoPh2 completed
Phase III U.S. trial initiation |
||||
BTQ2301 (latanoprost in EyeSol®) |
Dry Eye Disease (Elevated Intraocular Pressure) |
Global
|
||||
BTQ2302 (timolol & latanoprost combination) |
Dry Eye Disease (Elevated Intraocular Pressure) |
Global
|
||||
BTQ2401 (tacrolimus in in EyeSol®) |
Dry Eye Disease (Vernal Keratoconjunxtivitis, Severe Refractive Uveitis) |
Global
|
||||
NQ1910 IQDINE (iodine molecular in EyeSol®) |
Bacterial / Viral conjunctivitis |
Global
Expedited regulatory
path expected |
Topical Retina Therapies
EyeSol® Product | Indication | In-vitro | In-vivo | Tox | IND | Phase I/II | |
---|---|---|---|---|---|---|---|
NQ2010 (Peptide/NCE in EyeSol®) |
Diabetic Retinopathy (anti-ischemic neuroprotective) |
Global
|
|||||
NQ2020 (Protein in EyeSol®) |
Diabetic Retinopathy (anti-angiogenic) |
Global
|
|||||
NQ2030 (Small molecule in EyeSol®) |
Diabetic Retinopathy (anti-oxidant & anti-inflammatory) |
Global
|
|||||
NQ2040 (Peptide in EyeSol®) |
Diabetic Retinopathy (anti-angiogenic neuroprotective) |
Global
|
|||||
NQ2050 (Small molecule/NCE in EyeSol®) |
Diabetic Retinopathy (undisclosed) |
Global
|
Approved CE products: Novatears®, Novatears®+Omega-3